Europe Wants Safe AI. But Startups Need Clear Rules, Not Regulatory Fog

Europe has world-class researchers, strong universities, and serious technical talent. But when it comes to scaling AI startups, especially in healthcare, the region often makes the path harder than it needs to be.

The problem is not regulation itself. Healthcare AI should be regulated. These tools deal with sensitive data, clinical decisions, patient safety, and medical workflows. The real issue is uncertainty.

A healthcare AI startup in Europe may need to think about the EU AI Act, GDPR, Medical Device Regulation, cybersecurity rules, product liability, and different national healthcare systems at the same time. The EU AI Act entered into force in 2024 and is being phased in gradually, while high-risk AI guidance is still being clarified.

That creates a painful question for founders: is this product a clinical decision-support tool, a medical device, a general AI assistant, or a high-risk AI system? The answer can change the entire roadmap, cost base, and go-to-market plan.

OpenEvidence is a good example of what is at stake. According to Lukas Saari’s post, the US clinical AI tool has shut down access across Europe. Even without using it as the whole argument, it reflects a wider pattern: leading AI companies often delay, limit, or avoid European launches because regulatory risk is hard to price.

This matters because European clinicians may lose access to tools that could help with evidence search, guideline review, and workflow efficiency.

The capital environment makes it worse. Europe has less late-stage funding depth than the US, and the European Commission has acknowledged barriers including fragmented regulation, limited access to finance, talent shortages, and weak scale-up capital. Its proposed Scaleup Europe Fund is expected to exceed €10B, partly to address this gap. (Reuters)

So European founders face a double burden: build safer, more compliant products, but with less capital to scale.

The opportunity is still real. Europe could build healthcare AI companies that are trusted, compliant, and clinically embedded from day one. But startups need clearer classification, faster guidance, practical sandboxes, and more growth capital.

Key takeaway: Europe does not need no regulation. It needs clearer regulation. Otherwise, the US builds the tools, Europe writes the rules, and European clinicians wait.